603456 九洲药业
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)8.6477.13115.02018.65916.550
总资产报酬率 ROA (%)6.8455.51511.01212.32010.528
投入资产回报率 ROIC (%)7.9786.43913.19615.31312.717

边际利润分析
销售毛利率 (%)37.55233.78337.65634.66033.327
营业利润率 (%)21.92914.18821.28720.34718.548
息税前利润/营业总收入 (%)21.43912.64920.00618.68919.244
净利润/营业总收入 (%)17.99511.76418.67316.91415.607

收益指标分析
经营活动净收益/利润总额(%)106.083127.672105.670105.42098.121
价值变动净收益/利润总额(%)-0.323-1.113-1.640-3.0038.013
营业外收支净额/利润总额(%)-0.280-0.2170.413-0.371-1.194

偿债能力分析
流动比率 (X)3.3932.9673.8121.8041.809
速动比率 (X)2.4202.0252.6290.8911.003
资产负债率 (%)17.67522.62621.36932.11934.988
带息债务/全部投入资本 (%)2.9966.6386.92911.70817.404
股东权益/带息债务 (%)3,141.7821,362.1821,301.104720.957456.889
股东权益/负债合计 (%)462.130339.070364.874208.389185.813
利息保障倍数 (X)-50.038-8.385-14.610-11.81021.023

营运能力分析
应收账款周转天数 (天)70.30775.26253.23047.54162.786
存货周转天数 (天)182.404204.811208.092187.365189.485